Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyproterone acetate + ethinyl estradiol
- Development stage
- Phase 4
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cléo-35 is a combination pharmaceutical product developed by Altius Healthcare Group, containing the anti-androgen cyproterone acetate and the synthetic estrogen ethinyl estradiol. It is primarily indicated for the treatment of severe acne associated with androgenization (such as seborrhea or hirsutism) in women who have not responded to other treatments. Cyproterone acetate works by competitively inhibiting androgen receptors and reducing the synthesis of androgens, while ethinyl estradiol increases the levels of sex hormone-binding globulin (SHBG), thereby reducing the concentration of free, biologically active androgens in the blood. Although it functions as an oral contraceptive, it is specifically indicated for androgen-dependent conditions and should not be used solely for birth control.
- Brand names
- Cléo-35Cleo-35Cleo35Cleo 35
- Other names
- cyproterone acetate / ethinyl estradiolethinylestradiol / cyproterone acetate
02
Targets
AR (Adrenergic receptors)CYP1A1 (Cytochrome P450 1A1)CYP1A2 (Cytochrome P450 1A2)CYP2C8 (Cytochrome P450 2C8)CYP2J2 (Cytochrome P450 family 2 subfamily J member 2)ER (Estrogen receptor)GR (Glucocorticoid receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on cyproterone acetate + ethinyl estradiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyproterone acetate + ethinyl estradiol.